KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

[1]  D. Camidge,et al.  Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+advanced non-small cell lung cancer , 2021, Clinical Trials.

[2]  Mahmoud A. Bassal,et al.  Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer , 2021, Communications Biology.

[3]  M. Socinski,et al.  MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations , 2021, JCO precision oncology.

[4]  R. Heist,et al.  Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. , 2021, Cancer discovery.

[5]  G. Altavilla,et al.  A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations , 2021, Translational lung cancer research.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  S. Digumarthy,et al.  A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  R. Salgia,et al.  The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) , 2021, Cell reports. Medicine.

[9]  H. Nechushtan,et al.  The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. , 2021, Lung cancer.

[10]  Jianjun Zhang,et al.  Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer , 2021, Therapeutic advances in medical oncology.

[11]  Catherine Jorand Lebrun,et al.  SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations , 2020, iScience.

[12]  J. Johnston,et al.  A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses , 2020, NPJ vaccines.

[13]  L. Schwartz,et al.  A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). , 2020, Clinical lung cancer.

[14]  W. Liang,et al.  Driving the Improvement of Lung Cancer Prognosis. , 2020, Cancer cell.

[15]  D. Xuan,et al.  First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET , 2020, European Journal of Cancer.

[16]  Ming-Hai Wang,et al.  MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy , 2020, Journal of experimental & clinical cancer research : CR.

[17]  E. Longchampt,et al.  Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. , 2020, Lung cancer.

[18]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[19]  D. Camidge,et al.  1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort , 2020 .

[20]  E. Smit,et al.  1415TiP INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp) , 2020 .

[21]  N. Karachaliou,et al.  Abstract 3774: Unraveling mechanisms of resistance to tepotinib and future treatment options , 2020, Immunology.

[22]  Rongxiu Li,et al.  Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models , 2020, Frontiers in Oncology.

[23]  E. Feuer,et al.  The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.

[24]  E. Raso.  Splice variants of RAS—translational significance , 2020, Cancer and Metastasis Reviews.

[25]  R. Weiss.  A perspective on the early days of RAS research , 2020, Cancer and Metastasis Reviews.

[26]  A. Russo,et al.  KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting , 2020, Journal of thoracic disease.

[27]  W. Klepetko,et al.  Current therapy of KRAS-mutant lung cancer , 2020, Cancer and Metastasis Reviews.

[28]  Christopher S. Hughes,et al.  Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutations , 2020, bioRxiv.

[29]  N. Peled,et al.  Gender and lung cancer-SEER-based analysis. , 2020, Annals of epidemiology.

[30]  Prakash Kulkarni,et al.  Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies , 2020, Journal of clinical medicine.

[31]  L. Kong,et al.  Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing , 2020, OncoTargets and therapy.

[32]  R. Goody,et al.  KRasG12C inhibitors in clinical trials: a short historical perspective , 2020, RSC medicinal chemistry.

[33]  Ying Cheng,et al.  Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. , 2020, The Lancet. Respiratory medicine.

[34]  Jie Yang,et al.  Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. , 2020, The New England journal of medicine.

[35]  R. Heist,et al.  Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). , 2020 .

[36]  N. Girard,et al.  Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). , 2020 .

[37]  G. Frampton,et al.  Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. , 2020 .

[38]  Ying Cheng,et al.  Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). , 2020 .

[39]  J. Roth,et al.  Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  A. Markham.  Tepotinib: First Approval , 2020, Drugs.

[41]  M. Schuler,et al.  Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  M. Copin,et al.  Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  C. Paweletz,et al.  Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC , 2020, Clinical Cancer Research.

[44]  Qinghua Zhou,et al.  The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis , 2019, Front. Oncol..

[45]  R. Kurzrock,et al.  First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors , 2019, Clinical Cancer Research.

[46]  Jie Wu,et al.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer , 2019, Signal Transduction and Targeted Therapy.

[47]  D. Nam,et al.  Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts , 2019, Cancer science.

[48]  Diana Romero.  Two new agents target KRAS G12C , 2019, Nature Reviews Clinical Oncology.

[49]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[50]  G. Tobón,et al.  CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases , 2019, International reviews of immunology.

[51]  Y. Zimmer,et al.  A Comparative Analysis of Individual RAS Mutations in Cancer Biology , 2019, Front. Oncol..

[52]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[53]  T. Mitsudomi,et al.  Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  R. Schmid,et al.  New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness , 2019, Front. Oncol..

[55]  E. Collisson,et al.  Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer , 2019, Clinical Cancer Research.

[56]  Jia Wei,et al.  Tumor neoantigens: from basic research to clinical applications , 2019, Journal of Hematology & Oncology.

[57]  Young A Kim,et al.  MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function , 2019, International journal of molecular sciences.

[58]  J. Hadfield,et al.  RNA sequencing: the teenage years , 2019, Nature Reviews Genetics.

[59]  V. Apostolopoulos.  Cancer Vaccines: Research and Applications , 2019, Cancers.

[60]  Yue-Yin Pan,et al.  Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  Jeffrey W. Clark,et al.  Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. , 2019, Lung cancer.

[62]  A. Graber,et al.  Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses , 2019, Experimental and Molecular Therapeutics.

[63]  J. Neal,et al.  Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib , 2019, Anti-cancer drugs.

[64]  Yijun Wang,et al.  Targeting the untargetable KRAS in cancer therapy , 2019, Acta pharmaceutica Sinica. B.

[65]  E. Plimack,et al.  First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. , 2019, The oncologist.

[66]  H. Kluger,et al.  Results of a Phase II Placebo‐controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small‐cell Lung Carcinoma , 2019, Clinical lung cancer.

[67]  F. Galimi,et al.  Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours , 2019, British Journal of Cancer.

[68]  S. Tasaka,et al.  Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report , 2019, Thoracic cancer.

[69]  T. Yau,et al.  A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma , 2019, Therapeutic advances in medical oncology.

[70]  Zheng Wang,et al.  Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor , 2018, Cell.

[71]  Charles M. Rudin,et al.  Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[72]  Dong-Wan Kim,et al.  Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[73]  J. Nemunaitis,et al.  First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  A. Drilon,et al.  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  N. Agarwal,et al.  Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  L. Paz-Ares,et al.  KRAS-Mutant non-small cell lung cancer: From biology to therapy. , 2018, Lung cancer.

[77]  D. Bar-Sagi,et al.  Kras and Tumor Immunity: Friend or Foe? , 2018, Cold Spring Harbor perspectives in medicine.

[78]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[79]  K. Darwiche,et al.  MET Expression in Advanced Non–Small‐Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy , 2018, Clinical lung cancer.

[80]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[81]  Jian-zhong Wu,et al.  Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer , 2018, Molecular medicine reports.

[82]  F. Janku,et al.  A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer , 2018, Cancer Chemotherapy and Pharmacology.

[83]  J. H. Kim,et al.  Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis , 2018, Journal of Cancer.

[84]  B. Besse,et al.  Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment , 2018, Front. Oncol..

[85]  N. Kyprianou,et al.  Cell death under epithelial–mesenchymal transition control in prostate cancer therapeutic response , 2018, International journal of urology : official journal of the Japanese Urological Association.

[86]  In Seok Yang,et al.  Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients , 2018, BMC Bioinformatics.

[87]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[88]  J. Ahn,et al.  Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC , 2018, Clinical pharmacology in drug development.

[89]  F. Peng,et al.  Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping. , 2017, Lung cancer.

[90]  D. Cunningham,et al.  Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[91]  J. Landsberg,et al.  Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c‐MET Limit Cancer Immunotherapy , 2017, Immunity.

[92]  V. Meignin,et al.  MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon‐Based NGS Panels , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[93]  Min Zhang,et al.  HGF induces EMT in non-small-cell lung cancer through the hBVR pathway. , 2017, European journal of pharmacology.

[94]  E. Novellino,et al.  Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. , 2017, Journal of medicinal chemistry.

[95]  G. Woude,et al.  Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms , 2017, Molecular Cancer Therapeutics.

[96]  M. Socinski,et al.  Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer , 2017, Cancer.

[97]  P. Jänne,et al.  Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models , 2017, Clinical Cancer Research.

[98]  T. T. Poulsen,et al.  Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors , 2017, Clinical Cancer Research.

[99]  B. Zhong,et al.  Abstract 2096: Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models , 2017 .

[100]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[101]  Jeffrey W. Clark,et al.  Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). , 2017 .

[102]  M. Kris,et al.  Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database. , 2017 .

[103]  Huqin Zhang,et al.  Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies , 2017, Oncotarget.

[104]  H. Koeppen,et al.  A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. , 2017, The oncologist.

[105]  Jin-Hyoung Kang,et al.  Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma , 2017, Annals of Surgical Oncology.

[106]  Xin-Qiu Yao,et al.  Comparative structural dynamic analysis of GTPases , 2017, bioRxiv.

[107]  K. O'Byrne,et al.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[109]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[110]  M. Mazzone,et al.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma , 2016, Oncogene.

[111]  L. Rosen,et al.  A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer , 2016, Clinical Cancer Research.

[112]  C. Der,et al.  The role of wild type RAS isoforms in cancer. , 2016, Seminars in cell & developmental biology.

[113]  R. Salgia,et al.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.

[114]  John D. Minna,et al.  XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer , 2016, Nature.

[115]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[117]  E. Giovannetti,et al.  cMET Exon 14 Skipping: From the Structure to the Clinic. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[118]  Kedar S Vaidya,et al.  ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence , 2016, Clinical Cancer Research.

[119]  R. Camidge,et al.  Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[120]  Jeffrey W. Clark,et al.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[121]  P. Parren,et al.  A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. , 2016, Cancer research.

[122]  A. Redig,et al.  Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers. , 2016 .

[123]  Xiufeng Pang,et al.  Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK , 2016, Nature Communications.

[124]  U. Peters,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[125]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[126]  C. Martins,et al.  Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities , 2016, Nature.

[127]  S. Kobayashi,et al.  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. , 2015, Lung cancer.

[128]  Sheryl K Elkin,et al.  Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. , 2015, Clinical lung cancer.

[129]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[130]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[131]  K. Westover,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[132]  Z. Granot,et al.  MET is required for the recruitment of anti-tumoural neutrophils , 2015, Nature.

[133]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[134]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[135]  A. Kimmelman,et al.  Metabolic Dependencies in RAS-Driven Cancers , 2015, Clinical Cancer Research.

[136]  Frank McCormick,et al.  KRAS as a Therapeutic Target , 2015, Clinical Cancer Research.

[137]  Yunpeng Liu,et al.  Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer , 2015, Tumor Biology.

[138]  M. Ladanyi,et al.  Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[139]  A. Cox,et al.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif , 2015, Proceedings of the National Academy of Sciences.

[140]  Weiguo Qing,et al.  Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. , 2014, Journal of medicinal chemistry.

[141]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[142]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[143]  A. Iafrate,et al.  Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .

[144]  D. Atanackovic,et al.  TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer , 2014, Gene Therapy.

[145]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  G. Getz,et al.  A Genomics-Based Classification of Human Lung Tumors , 2013, Science Translational Medicine.

[147]  D. Aebersold,et al.  The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants , 2013, Molecular Cancer Therapeutics.

[148]  Patrick S Tarpey,et al.  What is next generation sequencing? , 2013, Archives of Disease in Childhood: Education & Practice Edition.

[149]  D. Nguyen,et al.  EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. , 2013, Cancer research.

[150]  Yi-long Wu,et al.  Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[151]  D. Dorsch,et al.  EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors , 2013, Clinical Cancer Research.

[152]  Ronglai Shen,et al.  Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers , 2012, Clinical Cancer Research.

[153]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[154]  A. Jemal,et al.  Increasing lung cancer death rates among young women in southern and midwestern States. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  John V Heymach,et al.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.

[156]  P. Ma,et al.  MET signaling: novel targeted inhibition and its clinical development in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[157]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[158]  M. Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[159]  K. Yamaguchi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[160]  Joseph Schoepfer,et al.  A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. , 2011, Cancer research.

[161]  J. Chiang,et al.  Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer , 2011, BMC Cancer.

[162]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[163]  P. Comoglio,et al.  Ron kinase transphosphorylation sustains MET oncogene addiction. , 2011, Cancer research.

[164]  Jie Qi,et al.  Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.

[165]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[166]  U. McDermott,et al.  Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. , 2010, Cancer research.

[167]  B. Elliott,et al.  Src and FAK mediate cell–matrix adhesion‐dependent activation of met during transformation of breast epithelial cells , 2009, Journal of cellular biochemistry.

[168]  G. V. Vande Woude,et al.  Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.

[169]  Y. Yatabe,et al.  Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[170]  Ravi Salgia,et al.  Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer , 2008, Journal of carcinogenesis.

[171]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition , 2008, Expert opinion on drug discovery.

[172]  N. Rosen,et al.  HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells , 2008, Molecular Cancer Therapeutics.

[173]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[174]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[175]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[176]  S. Thorgeirsson,et al.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[177]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[178]  C. Maroun,et al.  Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program. , 2003, Molecular biology of the cell.

[179]  R. Salgia,et al.  Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer , 2002, Journal of cellular and molecular medicine.

[180]  B. Vandenbunder,et al.  Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.

[181]  Giorgio F. Gilestro,et al.  The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met , 2002, Nature.

[182]  R. Jove,et al.  Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.

[183]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[184]  M. Stella,et al.  Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.

[185]  D. Stolz,et al.  Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.

[186]  K. Vuori,et al.  Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 – Crk signaling complex formation , 1999, Oncogene.

[187]  P. Comoglio,et al.  Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. , 1996, British Journal of Cancer.

[188]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[189]  D. Kamikura,et al.  Pathways Downstream of Shc and Grb2 Are Required for Cell Transformation by the Tpr-Met Oncoprotein* , 1996, The Journal of Biological Chemistry.

[190]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[191]  A. Bardelli,et al.  The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. , 1995, Oncogene.

[192]  Tetsuo Noda,et al.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor , 1995, Nature.

[193]  G. Rodrigues,et al.  Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. , 1994, Oncogene.

[194]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[195]  E. Medico,et al.  Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. , 1994, The Journal of biological chemistry.

[196]  P. Comoglio,et al.  Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. , 1993, The Journal of biological chemistry.

[197]  K. Willecke,et al.  Transforming activity of DNA fragments from normal human lymphocytes results from spontaneous activation of a c-Ha-ras1 gene , 1985, Molecular and cellular biology.

[198]  J. Feramisco,et al.  The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity , 1984, Nature.

[199]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[200]  J B Gibbs,et al.  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[201]  D. Goeddel,et al.  Comparative biochemical properties of normal and activated human ras p21 protein , 1984, Nature.

[202]  M. Wigler,et al.  Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1 , 1983, Nature.

[203]  G. Cooper,et al.  Transforming activity of human tumor DNAs. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[204]  H. Wakelee,et al.  Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer , 2017, Clinical lung cancer.

[205]  S. Ou,et al.  Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[206]  S. Ou,et al.  Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[207]  S. Ou,et al.  The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. , 2017, Lung cancer.

[208]  P. Scherle,et al.  Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. , 2010, Trends in molecular medicine.

[209]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[210]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[211]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[212]  M. Barbacid,et al.  Transforming genes in human tumors , 1982, Journal of cellular biochemistry.

[213]  W. Kirsten,et al.  Properties of a murine sarcoma virus. , 1970, Bibliotheca haematologica.